Collecting duct carcinoma is a rare and aggressive kidney cancer. It often causes blood in the urine, flank or back pain, and weight loss. Most people are diagnosed in adulthood, and the condition tends to progress quickly without treatment. Standard care includes surgery when possible, plus chemotherapy and targeted drugs, and some may receive immunotherapy. The outlook varies, but early diagnosis and prompt treatment can improve survival and quality of life.
Overview
Collecting duct carcinomaSymptoms
Collecting duct carcinoma often causes blood in the urine, flank or back pain, and sometimes a belly lump. Other signs include tiredness, fever, weight loss, or swelling from blocked urine flow; early symptoms of Collecting duct carcinoma may be subtle.
Outlook and prognosis
Collecting duct carcinoma tends to be aggressive, so many people are diagnosed after it has already spread. Outcomes vary, but earlier detection and combination treatments can help some live longer and feel better. Care at a center experienced with rare kidney cancers matters.
Causes and risk factors
The cause of collecting duct carcinoma isn’t clear. Risk may reflect combined factors: smoking, certain chemical exposures, chronic kidney disease, and rarely inherited syndromes or family history; many people develop it without any identifiable risk.
Genetic influences
Genetics matters in collecting duct carcinoma, but most cases aren’t clearly inherited. Tumor DNA often shows changes in pathways like SWI/SNF, NF2, or CDKN2A, which can guide trials or targeted care. Rarely, inherited syndromes (e.g., Lynch) increase risk.
Diagnosis
Diagnosis of Collecting duct carcinoma usually starts with imaging (CT or MRI) showing a kidney mass. A needle biopsy confirms the cancer. Doctors then stage it with additional scans and labs to check spread and plan treatment.
Treatment and drugs
Treatment for collecting duct carcinoma often combines surgery to remove the kidney and nearby tissue with chemotherapy tailored to this rare tumor. Many also receive targeted therapies or immunotherapy through clinical trials. Care is usually coordinated at centers experienced with rare kidney cancers.
Symptoms
At first, this kidney cancer can feel like common urinary troubles or just feeling off. Early symptoms of Collecting duct carcinoma may overlap with issues like infection or stones, which is why many people are diagnosed later. Symptoms vary from person to person and can change over time. See a clinician promptly if you notice blood in your urine, ongoing side or back pain, or a new lump.
Pink, red, or cola-colored urine can come and go. Clinicians call this hematuria, which means blood in the urine. With collecting duct carcinoma, bleeding may be painless.
A dull ache under the ribs or in the lower back can linger. It may worsen with movement or feel sharper during urination. In collecting duct carcinoma, pain often stays on one side.
You or a clinician may feel a firm area or fullness in the flank or belly. This can reflect a growing kidney mass. Collecting duct carcinoma can enlarge quickly.
Needing to urinate more often, burning, or difficulty starting the stream can occur. These changes can mimic a urinary infection. If symptoms don’t improve with usual treatment, ask about imaging.
How people usually first notice Collecting duct carcinoma?
Many people first notice collecting duct carcinoma when a dull ache or persistent pain develops in one side of the lower back or flank, sometimes with blood in the urine that may look pink, red, or cola-colored. Others are alerted by symptoms like unexplained tiredness, weight loss, fevers, or a new lump felt deep in the abdomen, and it’s often picked up on imaging done for these symptoms. Because this is a rare and aggressive kidney cancer, the “first signs of collecting duct carcinoma” are frequently subtle at the start and become clearer as pain, visible hematuria (blood in urine), or declining energy push someone to seek care.
Types of Collecting duct carcinoma
Collecting duct carcinoma is a rare kidney cancer that tends to grow and spread quickly, so spotting patterns early matters. Doctors recognize a few clinical variants based on how the tumor looks under the microscope and how it behaves, which can influence symptoms and treatment choices. People may notice different sets of symptoms depending on their situation. When reading about types of Collecting duct carcinoma, you’ll mostly see distinctions based on tumor grade and stage rather than many separate genetic subtypes.
Classic subtype
This variant arises from the kidney’s collecting (distal) ducts and often shows firm, irregular growths that can invade nearby tissue. Many have flank pain, blood in the urine, or fatigue from anemia, while doctors may find enlarged lymph nodes.
Medullary carcinoma
Seen almost exclusively in people with sickle cell trait or disease, it behaves very aggressively. Symptoms can come on quickly with flank pain, weight loss, and blood in the urine, and imaging often shows spread at diagnosis.
High-grade tumors
These look more abnormal under the microscope, grow faster, and are more likely to spread to lymph nodes, bones, or lungs. People often have more intense symptoms like persistent pain, night sweats, and unintentional weight loss.
Low-grade tumors
These appear closer to normal under the microscope and may grow more slowly. Symptoms can be milder or show up later, sometimes limited to intermittent blood in the urine or a dull ache in the side.
Metastatic disease
When cancer has spread beyond the kidney, symptoms depend on where it goes, such as bone pain, cough or shortness of breath, or abdominal fullness. Clinicians often describe them in these categories: local, regional, and distant spread.
What genetics can tell you about symptoms
Certain changes in FH or NF2 genes can make collecting duct carcinoma grow faster, causing symptoms like blood in urine, back or side pain, and fatigue. These variants push tumor cells to divide and invade nearby tissue, which can lead to weight loss and fever.
Causes and risk factors
The exact cause of collecting duct carcinoma is unknown. It likely starts when cells in the kidney’s collecting ducts develop DNA changes that let them grow unchecked. Doctors distinguish between risk factors you can change and those you can’t. Non-modifiable risks may include older age, being male, and a family history of kidney cancer, though collecting duct carcinoma itself is rarely inherited. Possible risk factors for collecting duct carcinoma include smoking, high blood pressure, obesity, long-term kidney disease or dialysis, and exposure to certain industrial solvents.
Environmental and biological risk factors
Collecting duct carcinoma is a rare kidney cancer, and most people never receive this diagnosis. Doctors often group risks into internal (biological) and external (environmental). Because it’s uncommon, environmental risk factors for collecting duct carcinoma aren’t firmly established, but research has identified a few patterns seen across kidney cancers. Right now, age and sex show clearer biological patterns for this cancer, while specific exposures remain under study.
Risk rises with advancing age. Many diagnoses occur in later adulthood, often in the 50s to 70s.
Men are diagnosed more often than women. The reason for this difference is not yet clear.
Workplace exposure to certain solvents (for example, trichloroethylene) has been linked to kidney cancers overall. A direct link to collecting duct carcinoma has not been confirmed.
Exposure to cadmium and related heavy metals has been associated with higher kidney cancer risk. Evidence specific to collecting duct carcinoma remains limited.
Genetic risk factors
In collecting duct carcinoma, most genetic changes arise within the kidney tumor cells rather than being passed down in families. Carrying a genetic change doesn’t guarantee the condition will appear. Understanding these genes can help tailor testing and, in some situations, guide checks before early symptoms of Collecting duct carcinoma are noticed. A few inherited syndromes can overlap, but a clear, consistent hereditary cause is uncommon.
Sporadic tumor mutations: Most cases are not inherited; the DNA changes are limited to the tumor cells. These are called somatic changes and they drive growth. They do not increase relatives’ risk.
NF2 alterations: Changes in the NF2 gene are seen in a subset of tumors. They can disrupt signals that control cell shape and growth, and have been reported in collecting duct carcinoma. These are usually somatic, not inherited.
SETD2 changes: Mutations in SETD2 and in genes that control how DNA is packaged and read appear in some cases. They can speed tumor growth in collecting duct carcinoma. Most are changes within the tumor only.
CDKN2A pathway loss: Loss of CDKN2A or its pathway reduces the cell’s brakes on division. This change is frequent in aggressive kidney cancers and has been described in collecting duct carcinoma. It is typically a tumor-acquired event.
TP53 tumor suppressor: Alterations in the TP53 gene can occur. When this guardian pathway is impaired, damaged cells survive and accumulate. These changes are generally not inherited.
Chromosomal instability: Many tumors show large chromosomal gains and losses rather than a single hotspot mutation. This genomic instability is linked with aggressive behavior. These broad changes are not known to be inherited in most people.
HLRCC overlap: Faults in the FH gene, seen in hereditary leiomyomatosis and renal cell cancer (HLRCC), can rarely produce tumors that resemble collecting duct cancers. Doctors may consider this if features of HLRCC are present or there is a strong family history. Genetic counseling can help decide on testing.
Family history signals: A family history of kidney cancer can point to an inherited predisposition, even though most collecting duct carcinoma is not familial. Patterns like younger age at diagnosis or several affected relatives may warrant genetics referral. In some cases, genetic testing can give a clearer picture of your personal risk.
Lifestyle risk factors
Collecting duct carcinoma is rare, so most lifestyle evidence comes from studies of kidney cancer in general. Still, several habits consistently relate to kidney cancer risk, and by extension may influence CDC risk and outcomes. Below are the lifestyle risk factors for Collecting duct carcinoma to consider, keeping in mind that these do not determine who gets CDC but can shift risk and affect overall health during care. These points reflect how lifestyle affects CONDITION through weight, metabolism, kidney workload, and exposure to carcinogens.
Smoking increases kidney cancer risk, likely by exposing the kidneys to carcinogens filtered from the bloodstream. Quitting reduces risk over time and supports better treatment tolerance.
Higher body fat raises kidney cancer risk through insulin resistance, chronic inflammation, and hormonal changes. Achieving and maintaining a healthy weight may lower risk and improve surgical and therapy outcomes.
Low activity contributes to weight gain and metabolic dysfunction tied to kidney cancer risk. Regular moderate exercise helps regulate insulin and inflammation, supporting lower risk and better recovery capacity.
Diets high in processed/red meats and low in fruits, vegetables, and whole grains are linked to higher kidney cancer risk. Emphasizing plants, fiber, and minimally processed foods may lower risk and improve cardiometabolic health during treatment.
Risk prevention
Collecting duct carcinoma is a rare kidney cancer, and there’s no guaranteed way to prevent it. Prevention is about lowering risk, not eliminating it completely. What helps most are general kidney cancer risk reducers: avoid tobacco, keep blood pressure and weight in a healthy range, and limit exposure to certain workplace chemicals. Paying attention to early symptoms of collecting duct carcinoma and staying up to date with checkups can also lead to earlier diagnosis and treatment.
Smoking raises the risk of kidney cancers, and stopping lowers that risk over time. While data in collecting duct carcinoma are limited, quitting still protects overall kidney and heart health.
High blood pressure is linked with a higher risk of kidney cancer. Aim for regular checks and treatment, plus salt awareness and daily movement to keep numbers in range.
Extra body weight is a known risk factor for kidney cancers. Gradual weight loss through balanced eating and activity can lower long-term risk.
Use proper ventilation and protective gear if you work with solvents or metals like trichloroethylene or cadmium. Reducing exposure may lower kidney cancer risk, including the rare collecting duct carcinoma.
Transmission
Collecting duct carcinoma isn’t contagious. It can’t be passed through everyday contact, kissing, sex, coughing, or sharing dishes, because it develops from changes in kidney cells, not a germ. Questions about how Collecting duct carcinoma is transmitted are common, but it isn’t; most cases are not inherited and happen by chance rather than running in families. The only rare exception is transmission through an organ transplant, and donor screening is designed to make this extremely unlikely.
When to test your genes
Consider genetic testing if you were diagnosed with collecting duct carcinoma, especially at a young age, have bilateral or multifocal kidney tumors, or a strong family history of kidney or related cancers. Testing can uncover inherited risks (e.g., FH, SDHB) and tumor mutations that guide targeted therapy or clinical trials. Ask your care team for referral to a genetic counselor.
Diagnosis
Collecting duct carcinoma is usually found after symptoms like blood in the urine, flank pain, or unexplained tiredness lead to imaging of the kidneys. Doctors confirm what they see on scans by testing a small tissue sample from the mass. Because this cancer can look like other kidney or urinary tract tumors, several steps are used to be sure. From here, the focus shifts to confirming or ruling out possible causes.
Your doctor asks about symptoms such as blood in urine, pain in the side, weight loss, or fevers. They examine your abdomen and back to check for tenderness or a lump.
Basic tests look for anemia, infection signs, and kidney function changes. Urine testing checks for blood and abnormal cells that suggest a tumor.
A quick, radiation-free scan can show a mass in the kidney. It helps decide whether more detailed imaging is needed.
Detailed CT images map the size and location of the kidney mass and nearby lymph nodes. This is a common first step in how collecting duct carcinoma is diagnosed, and it helps plan a biopsy.
Stages of Collecting duct carcinoma
Doctors stage collecting duct carcinoma using the standard kidney cancer system, which looks at tumor size, nearby structures, lymph nodes, and distant spread. Early and accurate diagnosis helps you plan ahead with confidence. Staging helps guide treatment choices and gives a sense of outlook, especially since early symptoms of collecting duct carcinoma can be subtle or mistaken for other issues.
Stage I
The tumor is 7 cm (about 2.8 in) or smaller and limited to the kidney. No spread to lymph nodes or distant organs.
Stage II
The tumor is larger than 7 cm (about 2.8 in) but still confined to the kidney. There’s no sign of spread to lymph nodes or other organs.
Stage III
The cancer has grown into nearby major veins or tissues around the kidney and/or has reached a nearby lymph node. There is still no distant spread.
Stage IV
The tumor has invaded beyond the tissue covering the kidney or into nearby organs, or it has spread to distant sites such as lungs, liver, or bones. This stage includes any distant metastasis or more extensive local invasion.
Outlook and prognosis
Looking at the long-term picture can be helpful. Collecting duct carcinoma is an aggressive kidney cancer, so the outlook depends a lot on how early it’s found and whether it has spread. Many people ask, “What does this mean for my future?”, and the honest answer is that outcomes vary widely because this cancer behaves differently from more common kidney tumors. When it’s caught at an early stage and removed completely, some people do well for years, but recurrence is still possible and close follow-up is key.
This brings us to what doctors call the outlook, or prognosis. If collecting duct carcinoma has spread to lymph nodes or distant organs at diagnosis—as it often does—the disease is harder to control and survival is shorter on average compared with typical renal cell carcinoma. Newer combinations of targeted drugs and immunotherapy can help some people live longer and feel better, but responses are mixed, and not everyone benefits. Many people find that symptoms such as flank pain, fatigue, or weight loss improve when treatment is working, then return if the cancer grows again.
The future may look uncertain now, but ongoing trials are expanding options and giving clearer guidance on treatment sequences. Asking early about clinical trials and the early symptoms of collecting duct carcinoma returning—such as new bone pain, worsening cough, or swelling in the legs—can help you and your team act quickly. Support from friends and family can make day-to-day care, travel for treatment, and recovery after surgery more manageable. Talk with your doctor about what your personal outlook might look like, including likely side effects, expected benefits, and how often to plan scans, so your care aligns with your goals.
Long-term effects
Collecting duct carcinoma is an aggressive kidney cancer that can have lasting health effects, especially when found at an advanced stage. Long-term effects vary widely, depending on tumor spread, response to therapy, and overall kidney function. Even when early symptoms of collecting duct carcinoma are subtle, the long-term picture is often driven by risks of spread, reduced kidney reserve, and treatment-related changes. Many people live with ongoing fatigue, pain, or anemia related to the cancer or its therapies.
Reduced kidney reserve can develop after tumor damage or removal of a kidney. This can lead to swelling, high blood pressure, or a need to avoid certain medicines.
The cancer can spread to nearby lymph nodes or distant organs over time. This may bring new symptoms and can shape overall outlook.
Spread to the lungs can cause cough, chest discomfort, or shortness of breath. Some notice reduced stamina with daily activities.
Bone spread can lead to pain, fragile bones, or fractures. Height loss or back pain may appear if the spine is involved.
How is it to live with Collecting duct carcinoma?
Living with collecting duct carcinoma often means juggling treatment schedules, scans, and fatigue while trying to keep daily routines steady. Many notice energy dips, pain in the back or side, changes in appetite, or weight loss, which can make work, caregiving, and social plans harder to manage. Loved ones often step into roles like driving to appointments, helping with meals and medication, and providing emotional support, and they may feel worry or burnout without clear communication and respite. People who build a team—oncology, palliative care for symptom relief, practical help at home, and honest check-ins with family—tend to find a steadier rhythm amid an unpredictable disease.
Treatment and drugs
Collecting duct carcinoma is rare and often aggressive, so treatment focuses on controlling the cancer, easing symptoms, and preserving kidney function when possible. Surgery to remove the tumor or the affected kidney is considered when the cancer is confined and a person is fit for an operation; if surgery isn’t possible or the cancer has spread, treatment usually shifts to systemic therapy. Doctors sometimes recommend a combination of lifestyle changes and drugs, including chemotherapy regimens commonly used for urothelial cancers, targeted therapies, and newer immunotherapies that help the immune system recognize cancer cells. Radiation may be used to relieve pain or treat spots that are causing symptoms, and supportive care can make a real difference in how you feel day to day. Not every treatment works the same way for every person, so your care team may adjust the plan over time and may suggest clinical trials to access promising therapies.
Non-drug treatment
Non-drug treatments for collecting duct carcinoma focus on removing or controlling tumor growth, easing symptoms, and maintaining day-to-day function. Many notice little to no warning signs at first—early symptoms of collecting duct carcinoma can be subtle—so plans are tailored to tumor stage and overall health. Beyond prescriptions, supportive therapies can help you stay active, manage pain, and prepare for surgery or radiation. Your care team will weigh benefits, risks, and recovery time with your goals and preferences.
Removing the kidney containing the main tumor can control cancer in the area. Surgeons may also remove nearby lymph nodes if they look involved. Recovery plans focus on pain control, movement, and bowel care.
In carefully chosen small tumors, partial kidney removal may be considered. This approach aims to spare kidney function while treating cancer. Not everyone with collecting duct carcinoma will be a candidate.
Targeted radiation can relieve pain and help control spread to bone or brain. It may also be used after surgery in select situations. Side effects are usually focused to the treated area.
Heat or cold can destroy small tumors in people who are not good candidates for surgery. These needle-guided treatments are done through the skin with imaging. Follow-up scans check response.
Your genes may have an impact on how drugs work for you
Two people can receive the same drug for collecting duct carcinoma yet respond differently because genes affect how tumors grow and how the body processes medicine. Testing tumor DNA and, sometimes, inherited genes can guide drug choice, dosing, and eligibility for targeted therapies.
Pharmacological treatments
Treatment for collecting duct carcinoma often starts with chemotherapy, with other options added based on how the cancer behaves and your overall health. Small studies support platinum-based combinations, and newer immunotherapies or targeted drugs may help some people, especially when the cancer has spread. Not everyone responds to the same medication in the same way. When possible, specialists also consider clinical trial options alongside standard care.
This is the most used first-line chemotherapy for collecting duct carcinoma. It’s given by IV in cycles and requires close checks of blood counts and kidney function. Nausea, fatigue, and infection risk are the most common side effects.
This is an alternative when cisplatin isn’t safe for the kidneys or overall fitness. It may be a bit less potent but is often better tolerated for those with reduced kidney function.
This immune checkpoint combination can shrink tumors in a subset of people with metastatic disease. Side effects come from an overactive immune system and can affect skin, gut, liver, lungs, or hormones; prompt reporting helps manage them.
Single-agent immunotherapy may be used if combination therapy isn’t a fit or after chemotherapy. Some responses can be long-lasting, though not everyone benefits.
Genetic influences
Most cases of collecting duct carcinoma seem to happen by chance rather than being passed down in families. It’s natural to ask whether family history plays a role. Right now, there isn’t a single inherited gene clearly tied to a higher hereditary risk of collecting duct carcinoma, and it usually does not run through generations. Doctors may consider genetic counseling and inherited cancer testing if it’s diagnosed at a younger age, involves both kidneys, or if several relatives have had kidney or related cancers, though this is uncommon. Testing the tumor itself can sometimes find gene changes that may help guide treatment choices or clinical trial options, even though those changes are not the same as inherited risk. Overall, genes can influence how the tumor behaves, but for most people with collecting duct carcinoma, a clear inherited cause isn’t found.
Is Collecting duct carcinoma genetic?
Genetics matters in collecting duct carcinoma, but most cases aren’t clearly inherited. Tumor DNA often shows changes in pathways like SWI/SNF, NF2, or CDKN2A, which can guide trials or targeted care. Rarely, inherited syndromes (e.g., Lynch) increase risk.
Pharmacogenetics—how genetics influence drug effects
Because this cancer is uncommon and treated with a few main approaches, doctors often look to the tumor’s genetics to help steer treatment. Beyond trial and error, genetics offers another way to match therapies: tumor genetic testing for collecting duct carcinoma looks for changes in the cancer cells that might respond to targeted drugs or immunotherapy. These results may guide your team toward medicines more likely to help—often through a clinical trial—and away from options with little expected benefit.
Your own genes can also influence how your body handles some medicines used for collecting duct carcinoma, including platinum chemotherapy, gemcitabine, and certain targeted tablets; this can affect side effects and the dose you need. Routine pharmacogenetic testing for these drugs isn’t standard yet, so clinicians usually monitor closely, adjust doses as needed, and check for drug–drug interactions, especially with liver‑metabolized tablets like cabozantinib. If the cancer appears at a young age or there’s a strong family history of kidney tumors, you may be offered testing for inherited risk; while this rarely changes the diagnosis of collecting duct carcinoma, it can guide screening and care planning for you and your family.
Interactions with other conditions
Because it starts deep in the kidney near the urine channels, collecting duct carcinoma can look a lot like other urinary problems. Certain diseases may “overlap,” meaning early symptoms of collecting duct carcinoma—blood in the urine, flank pain, fever—can resemble a kidney infection or kidney stones, so doctors often check for those first. It can also be confused with cancers that arise in the lining of the urinary tract (upper tract urothelial cancer), and in people with sickle cell trait, doctors carefully rule out renal medullary carcinoma, a different but similar‑appearing tumor.
Many living with collecting duct carcinoma also have high blood pressure, diabetes, or chronic kidney disease, and these can limit surgery choices and make some medicines riskier for the remaining kidney. Treatments such as platinum chemotherapy or certain immunotherapies can stress kidney function or flare autoimmune conditions, so plans are often adjusted and monitored closely. If the tumor blocks urine flow, recurrent urinary infections may occur and need prompt treatment before cancer therapy. With coordinated care between oncology, urology, and nephrology, many people live well despite having both cancer and other health issues.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described sudden, hard-to-explain weight loss, blood in the urine, and deep tiredness that didn’t match a person’s workload—signs we now recognize in some kidney cancers. Community stories often described the condition as a “silent” problem that showed itself late, often after back pain or a stubborn fever brought someone to a doctor. Those early observations set the stage for recognizing rare kidney tumors that behave differently from the more common types.
First described in the medical literature as a distinct tumor of the kidney’s drainage system, collecting duct carcinoma emerged from careful reviews of kidney cancer tissue under the microscope in the late 20th century. Doctors noticed that, unlike typical clear cell kidney cancers, these tumors started in the ducts that funnel urine out of the kidney and tended to spread early to nearby lymph nodes. Initially understood only through symptoms, later it became clear that its growth pattern and cell appearance were unique.
As medical science evolved, pathologists refined staining and imaging methods to separate collecting duct carcinoma from look‑alike tumors, including medullary carcinoma, a related cancer tied to sickle cell trait. This mattered because treatments and outlook differ. Over time, descriptions became more consistent across hospitals, which helped researchers track cases, share outcomes, and start clinical trials specific to this rare diagnosis.
Advances in genetics added another layer. Researchers found patterns in tumor DNA that helped explain its aggressive nature and guided the search for targeted medicines. Even so, collecting duct carcinoma remains uncommon, so much of its history has been built case by case, with international registries pooling information to speed progress. Despite evolving definitions, the core picture has stayed steady: a rare kidney cancer that arises in the kidney’s collecting system and often needs swift, coordinated care.
In recent decades, awareness has grown among urologists, oncologists, and radiologists, leading to earlier biopsies when scans show tumors centered in the kidney’s inner region. Looking back helps explain why older reports mixed these cancers with other kidney tumors—diagnostic tools were limited, and the differences are subtle. Today, clearer criteria and multidisciplinary review have improved accuracy, giving people with collecting duct carcinoma a more precise diagnosis and, increasingly, access to studies testing new therapies.